137 related articles for article (PubMed ID: 35561666)
1. Construction of a hypoxia-immune-related prognostic model and targeted therapeutic strategies for cervical cancer.
Xie S; Ding B; Wang S; Zhang X; Yan W; Xia Q; Meng D; Shen S; Yu B; Liu H; Hu J; Wang S
Int Immunol; 2022 Jul; 34(7):379-394. PubMed ID: 35561666
[TBL] [Abstract][Full Text] [Related]
2. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
[TBL] [Abstract][Full Text] [Related]
3. Identification of a prognostic model based on immune and hypoxia-related gene expressions in cervical cancer.
Wang L; Wang C; He Y; Jin M; Lin L; Jiao X; Hu X; Wang Y
J Obstet Gynaecol; 2023 Dec; 43(2):2277242. PubMed ID: 37938121
[TBL] [Abstract][Full Text] [Related]
4. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
6. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
Xu HH; Wang HL; Xing TJ; Wang XQ
Front Immunol; 2022; 13():851622. PubMed ID: 35924232
[TBL] [Abstract][Full Text] [Related]
7. The Role of High-Risk Human Papillomavirus-Related Long Non-Coding RNAs in the Prognosis of Cervical Squamous Cell Carcinoma.
Cheng Y; Yang S; Shen Y; Ding B; Wu W; Zhang Y; Liang G
DNA Cell Biol; 2020 Apr; 39(4):645-653. PubMed ID: 32045269
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
9. Construction of Immune-Associated Nomogram for Predicting the Recurrence Survival Risk of Stage I Cervical Cancer.
Wang Y; Zhang L; Wang B; Cheng Y
Biomed Res Int; 2021; 2021():6699131. PubMed ID: 34337046
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of a prognostic signature related to hypoxic tumor microenvironment in cervical cancer.
Nie C; Qin H; Zhang L
PLoS One; 2022; 17(6):e0269462. PubMed ID: 35657977
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of an immune-associated RNA-binding proteins signature to predict clinical outcomes and therapeutic responses in colon cancer patients.
Sun D; Yang KS; Chen JL; Wang ZB
World J Surg Oncol; 2021 Oct; 19(1):314. PubMed ID: 34702278
[TBL] [Abstract][Full Text] [Related]
12. A hypoxia-related prognostic model predicts overall survival and treatment response in hepatocellular carcinoma.
Xing J; Shen S; Liu X; Zhang Y
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36314455
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of a seven-gene prognostic marker in colon cancer based on single-cell transcriptome analysis.
Zhou Y; Guo Y; Wang Y
IET Syst Biol; 2022 Apr; 16(2):72-83. PubMed ID: 35352485
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy.
Liu J; Wang Y; Mei J; Nie S; Zhang Y
Front Cell Dev Biol; 2021; 9():671736. PubMed ID: 34368124
[TBL] [Abstract][Full Text] [Related]
15. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
16. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.
Zhang H; Kong W; Zhao X; Han C; Liu T; Li J; Song D
BMC Genom Data; 2022 Jan; 23(1):8. PubMed ID: 35042477
[TBL] [Abstract][Full Text] [Related]
17. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
18. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
19. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
Lai J; Xu T; Yang H
BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
[TBL] [Abstract][Full Text] [Related]
20. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients.
Lv W; Yao Q
Dis Markers; 2022; 2022():9428660. PubMed ID: 35069936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
